Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Remifentanil for Crush Injury-Induced AKI in Rats
NCT07094165Completed
- Sponsor
- Ankara City Hospital
- Start
- Jul 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of dexmedetomidine in acute kidney injury (AKI) (4 arms), sponsored by Ankara City Hospital. Primary endpoint: Serum Creatinine Level at 6 hours. Started Jul 2024; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07094165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094165.